Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

SKY-0515 for Huntington's Disease Dementia

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19832763

SKY-0515 for Huntington's Disease Dementia

Abstract

Huntington's disease causes progressive dementia through mutant huntingtin protein toxicity. SKY-0515 mechanism is not fully disclosed but targets Huntington's pathophysiology. The compound is in Phase 2/3 trials, suggesting advanced development for this rare dementia subtype with no current disease-modifying treatments.

Powered by OpenAIRE graph
Found an issue? Give us feedback